Historical Archives

Media Contacts:
Kristy Marks
Kristy.marks@bausch.com
(908) 927-0683

Teresa Panas
teresa@tgpcomm.com
(973) 809-8590

BAUSCH + LOMB ANNOUNCES NEW SCIENTIFIC AND CLINICAL ANALYSES TO BE PRESENTED DURING THE AMERICAN ACADEMY OF OPHTHALMOLOGY MEETING IN SAN FRANCISCO

Surgeons Invited to Gain Hands-on Experience of Latest Surgical Innovations at Booth #6266 Company Also Sponsors Educational Events, Run for Vision

BRIDGEWATER, N.J., Oct. 7, 2019 – Bausch + Lomb, a leading global eye health company, today announced that eight new scientific poster and clinical presentations involving the company’s products, as well as data from the company’s Antibiotic Resistance Monitoring in Ocular MicRoorganisms (ARMOR) surveillance study, will be presented during the Annual Meeting of the American Academy of Ophthalmology (AAO) in San Francisco (Oct. 12-15, 2019).

In addition, the company will provide surgeons the opportunity to gain hands-on experience with a variety of products from its comprehensive Surgical portfolio, including the full family of enVista^® IOLs and Storz^® Instruments, at its exhibit booth (#6266), and sponsor educational events as well as the Bausch + Lomb-sponsored Run for Vision.

“Bausch + Lomb’s mission is to help people see better to live better, so we are committed to supporting the eye care community in a variety of ways,” said Joe Gordon, U.S. president, Bausch + Lomb. “Whether it’s supporting important research that yields valuable new clinical insights, creating opportunities for surgeons to learn more about our products or sponsoring events that help raise awareness about important issues, we are proud to do everything we can to support eye care professionals and enhance patient care and outcomes.”

Scientific and Clinical Analyses
The full schedule of all scientific poster and clinical presentations that will include Bausch + Lomb products and the ARMOR study results is as follows:

• Asbell, P et al. “Ten-Year Antibiotic Resistance Trends From Ocular Pathogens Collected in the ARMOR Surveillance Study.” Saturday, Oct. 12, 2019 at 9:00 a.m. to Tuesday, Oct. 15, 2019 at 1:00 p.m.
• DeCory H et al. “Antibiotic Resistance Among Intraocular Bacterial Pathogens Collected Over 10 Years in ARMOR.” Saturday, Oct. 12, 2019 at 9:00 a.m. to Tuesday, Oct. 15, 2019 at 1:00 p.m.
• Harasymowycz, P et al. “Effectiveness of Latanoprostene Bunod in Treating OAG and OHT: Network Meta-analysis.” Saturday, Oct. 12, 2019 at 9:00 a.m. to Tuesday, Oct. 15, 2019 at 1:00 p.m., also available as part of e-poster discussion session on Sunday, Oct. 12, 2019 from 12:15-12:45 e-poster Lounge, Station 3
• Liang, E et al. “Retinal Image Simulations of Aspheric IOLs With Nominal Tilt and Decentration.” Saturday, Oct. 12, 2019 at 9:00 a.m. to Tuesday, Oct. 15, 2019 at 1:00 p.m.
• Packer, M et al. “Optimizing Refractive Outcomes With a New Vergence-Based Algorithm for a Neutral Aspheric Monofocal Toric IOL.” Saturday, Oct. 12, 2019 at 9:00 a.m. to Tuesday, Oct. 15, 2019 at 1:00 p.m., also available as part of e-poster discussion session on Monday, Oct. 14, 2019 from 1:15-2:15 p.m., e-poster Lounge, Station 5
• Pizio, H et al. “Energy-Fluid Metrics Analysis of Patients Undergoing Vacuum-Based Phacoemulsification From Cloud-Based Database.” Saturday, Oct. 12, 2019 at 9:00 a.m. to Tuesday, Oct. 15, 2019 at 1:00 p.m.
• Rocha, K. et al. “Analysis of Static and Dynamic Factors Associated With Pseudoaccommodation in Monofocal IOLs.” Friday, Oct. 11, 2019 at 7:00 a.m. to Tuesday, Oct. 15, 2019 at 1:00 p.m.
• Stephenson, Dee G et al. “Retinal Image Simulations of Aspheric Toric IOLs Under Conditions of Tilt and Decentration.” Saturday, Oct. 12, 2019 at 9:00 a.m. to Tuesday, Oct. 15, 2019 at 1:00 p.m.

Hands-on Experience at the Booth
Throughout the meeting at the Bausch + Lomb booth, surgeons will have the opportunity to gain hands-on experience with some of the company’s latest surgical innovations. This includes the full family of enVista^® IOLs and Storz^® Instruments. Other innovations from the Bausch + Lomb Consumer Health Care, Pharmaceuticals and Surgical divisions will also be featured.

Educational Events
Friday, Oct. 11
Surgeons are invited to attend the “enVista® toric: Fixed on Stability. Focused on Outcomes” at Morton’s Steakhouse (400 Post Street, San Francisco) from 6:30-9:30 p.m. Drs. Mitchell Shultz and Doug Katsev will discuss their experiences using the company’s glistening-free hydrophobic acrylic intraocular lens for astigmatism correction.

Saturday, Oct. 12
Surgeons are also invited to engage in a dynamic conversation during the “Complex Cataract Cases: Learn with the Experts” event at One Market Restaurant (1 Market Street, San Francisco). Throughout the evening, Drs. Audrey Rostov and Robert Weinstock will present four complex cataract surgery cases, focusing on patients with early age related macular changes, mild allergic conjunctivitis with intolerance to soft contact lenses, post-refractive surgery blepharitis and previous laser vision correction. Registration will begin at 7:00 p.m., with the program following at 7:30 p.m. Attendees are asked to register in advance at http://bit.ly/LearnwiththeExperts.

34th Annual Run for Vision in Support of Eye Tissue Donation
AAO attendees are invited to join donor family members and corneal transplant recipients for the annual Run for Vision, a 5k benefit run/walk, to be held at Golden Gate Park in the Peacock Meadow (located on JFK Drive, San Francisco) on Sunday, Oct. 13 at 6:30 a.m. Bausch + Lomb has sponsored Run for Vision since its inception more than 30 years ago. Proceeds from the event help raise awareness and monetary support for eye tissue donation on behalf of the Eye Bank Association of America.

Those interested in participating can register at the Bausch + Lomb booth (#6266) during the conference or online at https://www.raceentry.com/races/ebaas-run-for-vision-5k/2019/register. Pre-registered participants can pick up their race packets, including runner bib and commemorative running shirt, at the Bausch + Lomb booth between 9 a.m. and 5 p.m. on Saturday, Oct. 12.

Important Safety Information for BESIVANCE® (besifloxacin ophthalmic suspension) 0.6%

INDICATION
BESIVANCE® (besifloxacin ophthalmic suspension) 0.6% is a quinolone antimicrobial indicated for the treatment of bacterial conjunctivitis caused by susceptible isolates of the following bacteria:Aerococcus viridans*, CDC coryneform group G, Corynebacterium pseudodiphtheriticum*, Corynebacterium striatum*, Haemophilus influenzae, Moraxella catarrhalis*, Moraxella lacunata*, Pseudomonas aeruginosa*, Staphylococcus aureus, Staphylococcus epidermidis, Staphylococcus hominis*, Staphylococcus lugdunensis*, Staphylococcus warneri*, Streptococcus mitis group, Streptococcus oralis, Streptococcus pneumoniae, Streptococcus salivarius*

*Efficacy for this organism was studied in fewer than 10 infections.

IMPORTANT SAFETY INFORMATION

• BESIVANCE^® is not for injection into the eye.
• As with other anti-infectives, prolonged use of BESIVANCE^® may result in overgrowth of non-susceptible organisms, including fungi. If super-infection occurs, discontinue use and institute alternative therapy.
• Patients should not wear contact lenses if they have signs or symptoms of bacterial conjunctivitis or during the course of therapy with BESIVANCE^®.
• The most common adverse event reported in approximately 2% of patients treated with BESIVANCE^® was conjunctival redness. Other adverse events reported in patients receiving BESIVANCE^® occurring in approximately 1-2% of patients included: blurred vision, eye pain, eye irritation, eye pruritus and headache.
• Safety and effectiveness in infants below one year of age have not been established.

Click here for Prescribing Information for BESIVANCE^®.

Important Safety Information for VYZULTA^® (latanoprostene bunod ophthalmic solution), 0.024%

INDICATION
VYZULTA^® (latanoprostene bunod ophthalmic solution), 0.024% is indicated for the reduction of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.

IMPORTANT SAFETY INFORMATION

• Increased pigmentation of the iris and periorbital tissue (eyelid) can occur. Iris pigmentation is likely to be permanent
• Gradual changes to eyelashes, including increased length, increased thickness, and number of eyelashes, may occur. These changes are usually reversible upon treatment discontinuation
• Use with caution in patients with a history of intraocular inflammation (iritis/uveitis). VYZULTA should generally not be used in patients with active intraocular inflammation
• Macular edema, including cystoid macular edema, has been reported during treatment with prostaglandin analogs. Use with caution in aphakic patients, in pseudophakic patients with a torn posterior lens capsule, or in patients with known risk factors for macular edema
• There have been reports of bacterial keratitis associated with the use of multiple-dose containers of topical ophthalmic products that were inadvertently contaminated by patients
• Contact lenses should be removed prior to the administration of VYZULTA and may be reinserted 15 minutes after administration
• Most common ocular adverse reactions with incidence =2% are conjunctival hyperemia (6%), eye irritation (4%), eye pain (3%), and instillation site pain (2%)

Please see full prescribing information at www.Vyzulta.com.

About Bausch + Lomb
Bausch + Lomb, a wholly owned subsidiary of Bausch Health Companies Inc., is a leading global eye health organization that is solely focused on helping people see better to live better. Its core businesses include over-the-counter products, dietary supplements, eyecare products, ophthalmic pharmaceuticals, contact lenses, lens care products, ophthalmic surgical devices and instruments. Bausch + Lomb develops, manufactures and markets one of the most comprehensive product portfolios in the industry, which is available in more than 100 countries. For more information, visit www.bausch.com.  

###

®/™ are trademarks of Bausch & Lomb Incorporated or its affiliates.
Any other product/brand names are trademarks of the respective owners. 
© 2018 Bausch & Lomb Incorporated or its affiliates. . 
MTB.0449.USA.19